🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

48 results for “LEO” Clear

  1. Adtralza 150 mg solution for injection in pre-filled syringe, The placebo presentation is a pre-filled syringe containing the same excipients in the same amounts as the IMP.

    LEO Pharma A/S

    Treatment of moderate-to-severe Atopic dermatitis

    phase 3 small molecule active

    1 trial

  2. Doxorubicinhydrochlorid Teva® 2 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bleomycin 15000 IU Powder for solution for injection/infusion, Detimedac 200 mg, Pulver zur Herstellung einer Injektions-/Infusionslösung, Doxorubicin hydrochloride 2 mg/ml solution for infusion, ADCETRIS 50 mg powder for concentrate for solution for infusion, Vinblastine Sulfate 1 mg/ml solution for injection, Dacarbazine medac 200 mg, powder for solution for injection/infusion, Vinblastinsulfat Teva® 1 mg/ml Injektions

    Takeda Pharmaceuticals International AG

    Advanced Classical Hodgkin Lymphoma

    phase 3 small molecule active

    1 trial

  3. INZ-701

    BioMarin International Limited

    Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency

    phase 3 small molecule active

    2 trials

  4. INZ-701

    Pharma Mar S.A.

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency

    phase 3 small molecule active

    1 trial

  5. INZ-701, INZ-701

    Pharma Mar S.A.

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency

    phase 3 small molecule active

    1 trial

  6. Medpulser Electroporation with Bleomycin

    INOVIO PHARMACEUTICALS, INC.

    Head Neck Cancer

    phase 3 other terminated

    1 trial

  7. The placebo has the same composition as the investigational medicinal product Clinitrat® (6.563+175,4+89,3+23,3) mg/sachet (with the exception of the active substance), is manufactured by the same manufacturer (uni-pharma kleon tsetis pharmaceutical laboratory s.a) and is not sterile., CLINITRAT® (6.563+175,4+89,3+23,3) mg/sachet ή stick, Κόνις για πόσιμο διάλυμα

    Pharma Mar S.A.

    Second line treatment for colonoscopy preparation

    phase 3 small molecule active

    1 trial

  8. Trabectedin EVER Pharma 1 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, Pazopanib PharOS 200 mg film-coated tablets, HALAVEN 0.44 mg/ml solution for injection

    INTENSITY THERAPEUTICS, INC.

    liposarcoma (dedifferentiated, myxoid, round cell or pleomorphic), Leiomyosarcoma (non-uterine), Undifferentiated pleomorphic sarcoma

    phase 3 small molecule active

    1 trial

  9. A prospective, multi-centre study (B-Sure) to evaluate long-term durability of treatment response in chronic hepatitis B participants with and without nucleos(t)ide therapy who have participated in a previous bepirovirsen treatment study.

    GlaxoSmithKline Biologicals S.A.

    Chronic Hepatitis B

    phase 2 other active

    1 trial

  10. AZD7798 Placebo: 0.9% saline solution for injection, commercially available., AZD7798

    AstraZeneca AB

    Crohn’s Disease and an Ileostomy

    phase 2 small molecule active

    1 trial

  11. Adtralza 150 mg solution for injection in pre-filled syringe

    LEO Pharma A/S

    Treatment of moderate-to-severe Atopic dermatitis

    phase 2 small molecule active

    1 trial

  12. BLEOMYCIN

    Fondazione Telethon ETS

    colorectal cancer

    phase 2 small molecule active

    1 trial

  13. BLEOMYCIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, VINBLASTINE , CYCLOPHOSPHAMIDE , ETOPOSIDE , DACARBAZINE , PREDNISOLONE, VINCRISTINE , PREDNISONE, DOXORUBICIN

    Merck Sharp and Dohme

    Classical Hodgkin lymphoma in children and young adults

    phase 2 small molecule active

    1 trial

  14. BLEOMYCIN, CISPLATIN

    Fondazione Telethon ETS

    patients with newly diagnosed or recurrent high-grade or initially invasive precancerous squamous lesions of the vulva and non-invasive vulvar Paget's disease

    phase 2 small molecule active

    1 trial

  15. BLEOPRIM 15 mg polvere per soluzione iniettabile, Carboplatino AHCL 10 mg/ml Concentrato per soluzione per infusione

    Istituto Gentili S.r.l.

    relapsing vulvar carcinoma already subjected to multiple treatments

    phase 2 small molecule active

    1 trial

  16. BLEOPRIM 15 mg polvere per soluzione iniettabile, Fluorouracil 50 mg/ml Solution for Injection or Infusion, LEDERFOLIN 25 mg Polvere per soluzione iniettabile per uso endovenoso, CAMPTO 20 mg/mL concentrate for solution for infusion, Oxaliplatin 5 mg/ml Concentrate for Solution for infusion

    Fondazione Telethon ETS

    Locally Advanced Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  17. BLEOPRIM 15 mg polvere per soluzione iniettabile, Fluorouracile Teva 250 mg/5 ml soluzione per infusione, CARBOPLATINO TEVA 10 mg/ml concentrato per soluzione per infusione, CETUXIMAB, PEMBROLIZUMAB, Cisplatino Teva Italia 0,5 mg/ml concentrato per soluzione per infusione

    Fondazione Telethon ETS

    CARCINOMA OF THE ORAL CAVITY AND OROPHARYNX

    phase 2 small molecule active

    1 trial

  18. Bleomycin

    China SXT Pharmaceuticals

    Lymphatic Malformation

    phase 2 small molecule active

    1 trial

  19. Bleomycin medac, 15 000 RÜ süstelahuse pulber

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    VASCULAR MALFORMATION

    phase 2 small molecule active

    1 trial

  20. CABOMETYX 40 mg film-coated tablets, CABOMETYX 20 mg film-coated tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma.

    phase 2 small molecule active

    1 trial

  21. Delgocitinib cream, Cream Vehicle

    LEO Pharma A/S

    Mild to severe palmoplantar pustulosis

    phase 2 small molecule active

    1 trial

  22. Exon 51 specific phosphorothioate oligonucleotide

    BioMarin International Limited

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  23. Exon 51 specific phosphorothioate oligonucleotide

    BioMarin International Limited

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  24. INZ-701

    Pharma Mar S.A.

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency and ATP-binding cassette sub-family C member 6 (ABCC6) Deficiency, Generalized Arterial Calcification of Infancy (GACI), Pseudoxanthoma elasticum (PXE)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources